Figure 3.
Hepcidin, EPO, and ERFE concentrations in patients treated for tuberculosis (N = 18) before (0 weeks) and during intensive (2-8 weeks) and continuation (10-24 weeks) phase antituberculosis treatment as well as after a 2-week follow-up (26 weeks). (A) Hepcidin. (B) Erythropoietin. (C) Erythroferrone. Graphs show geometric mean and 95% CI. Different time points were compared by using LMM with repeated measures followed by Bonferroni correction for multiple-comparison testing. Time points without any common letter significantly differ from each other (P < .05).

Hepcidin, EPO, and ERFE concentrations in patients treated for tuberculosis (N = 18) before (0 weeks) and during intensive (2-8 weeks) and continuation (10-24 weeks) phase antituberculosis treatment as well as after a 2-week follow-up (26 weeks). (A) Hepcidin. (B) Erythropoietin. (C) Erythroferrone. Graphs show geometric mean and 95% CI. Different time points were compared by using LMM with repeated measures followed by Bonferroni correction for multiple-comparison testing. Time points without any common letter significantly differ from each other (P < .05).

Close Modal

or Create an Account

Close Modal
Close Modal